Millennium Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-10,749
| Closed | -$132K | – | 6882 |
|
|
2023
Q2 | $132K | Sell |
10,749
-29,455
| -73% | -$368K | ﹤0.01% | 5259 |
|
|
2023
Q1 | $494K | Buy |
40,204
+23,219
| +137% | +$273K | ﹤0.01% | 4609 |
|
|
2022
Q4 | $195K | Buy |
+16,985
| New | +$140K | ﹤0.01% | 5349 |
|
|
2021
Q3 | – | Sell |
-11,187
| Closed | -$71K | – | 7664 |
|
|
2021
Q2 | $71K | Sell |
11,187
-1,105
| -9% | -$7.29K | ﹤0.01% | 6320 |
|
|
2021
Q1 | $77K | Buy |
+12,292
| New | +$87.9K | ﹤0.01% | 5729 |
|
|
2019
Q2 | – | Sell |
-13,349
| Closed | -$73K | – | 4771 |
|
|
2019
Q1 | $73K | Sell |
13,349
-22,473
| -63% | -$103K | ﹤0.01% | 3881 |
|
|
2018
Q4 | $109K | Sell |
35,822
-134,047
| -79% | -$465K | ﹤0.01% | 3531 |
|
|
2018
Q3 | $712K | Sell |
169,869
-47,353
| -22% | -$200K | ﹤0.01% | 3056 |
|
|
2018
Q2 | $839K | Buy |
217,222
+50,080
| +30% | +$333K | ﹤0.01% | 2933 |
|
|
2018
Q1 | $1.06M | Sell |
167,142
-92,861
| -36% | -$768K | ﹤0.01% | 2656 |
|
|
2017
Q4 | $2.1M | Buy |
260,003
+178,660
| +220% | +$1.67M | ﹤0.01% | 2251 |
|
|
2017
Q3 | $931K | Sell |
81,343
-27,991
| -26% | -$294K | ﹤0.01% | 2560 |
|
|
2017
Q2 | $1.07M | Buy |
109,334
+54,998
| +101% | +$1.12M | ﹤0.01% | 2419 |
|
|
2017
Q1 | $1.32M | Buy |
54,336
+38,528
| +244% | +$964K | ﹤0.01% | 2239 |
|
|
2016
Q4 | $507K | Sell |
15,808
-232,076
| -94% | -$9.9M | ﹤0.01% | 2668 |
|
|
2016
Q3 | $12.4M | Sell |
247,884
-12,229
| -5% | -$508K | 0.02% | 814 |
|
|
2016
Q2 | $11M | Buy |
+260,113
| New | +$14.2M | 0.03% | 799 |
|
|
2016
Q1 | – | Sell |
-180,138
| Closed | -$11.2M | – | 3900 |
|
|
2015
Q4 | $11.2M | Buy |
+180,138
| New | +$12.7M | 0.02% | 868 |
|
|
2015
Q3 | – | Sell |
-32,983
| Closed | -$3.21M | – | 3923 |
|
|
2015
Q2 | $3.21M | Sell |
32,983
-80,455
| -71% | -$7.66M | 0.01% | 1650 |
|
|
2015
Q1 | $10.6M | Sell |
113,438
-115,068
| -50% | -$9.79M | 0.02% | 980 |
|
|
2014
Q4 | $20.3M | Sell |
228,506
-24,578
| -10% | -$1.79M | 0.04% | 591 |
|
|
2014
Q3 | $17.5M | Sell |
253,084
-8,182
| -3% | -$437K | 0.04% | 567 |
|
|
2014
Q2 | $15M | Buy |
261,266
+222,134
| +568% | +$11.3M | 0.04% | 616 |
|
|
2014
Q1 | $1.55M | Buy |
39,132
+14,265
| +57% | +$610K | ﹤0.01% | 1956 |
|
|
2013
Q4 | $1.04M | Buy |
24,867
+731
| +3% | +$21.2K | ﹤0.01% | 2261 |
|
|
2013
Q3 | $720K | Buy |
24,136
+21,264
| +740% | +$744K | ﹤0.01% | 2326 |
|
|
2013
Q2 | $152K | Buy |
+2,872
| New | +$126K | ﹤0.01% | 2816 |
|
Other funds holding MACK
WSL
NM
MAP
SC
SCM
WIM
Millennium Management's MACK Position: Q3 2023 in Review
Millennium Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2023, closing a stake of 10,749 shares — an estimated $132K sold.
Millennium Management first reported a position in MACK in Q2 2013 and held it in 27 quarters. The position peaked at $20.3M in Q4 2014. 63 funds tracked by Wall St. Rank hold MACK as of Q3 2023.
- Millennium Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Millennium Management sold 10,749 Merrimack Pharmaceuticals, Inc. shares in Q3 2023, an estimated $132K.
- Millennium Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 27 quarters.
- Millennium Management's Merrimack Pharmaceuticals, Inc. position peaked at $20.3M in Q4 2014.
- 63 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2023.
Based on Millennium Management's 13F filing for Q3 2023, filed 14 Nov 2023.